• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 15, 2017

View Archived Issues

Appointments and advancements

Sangamo Biosciences Inc., of Richmond, Calif., appointed Kathy Yi senior vice president and chief financial officer. Read More

In the clinic

Lung Therapeutics Inc., of Austin, Texas, said it enrolled the first patient in a phase Ia/Ib trial testing LTI-01, designed to treat loculated pleural effusions. Read More

Other news to note

Twoxar Inc., of Palo Alto, Calif., said its liver cancer candidate, TXR-311, demonstrated positive results in cell-based assays. In a panel of genetically diverse hepatocellular carcinoma (HCC) cell lines, TXR-311 was shown to be potently cytotoxic with an average half maximal inhibitory concentration (IC50) in the nanomolar range. Read More

Financings

Anthera Pharmaceuticals Inc., of Hayward, Calif., said it priced a public offering of 30 million shares of common stock at 50 cents per share and two tranches of warrants to purchase an aggregate of 60 million shares of common stock. Read More

EBG petitions FDA to limit term of review of combo product appeals

The regulatory law firm of Epstein Becker Green (EBG) has petitioned the FDA to set a limit to the number of days the agency can take to review petitions regarding combo product designations, stating that as matters stand, the agency is “unaccountable for egregious delays in decision-making.” Read More

Japan’s MHLW looks to build entrepreneurial biomedical ecosystem

TOKYO – Despite being home to world-class biomedical research and large innovative drug and device companies, a lack of an entrepreneurial ecosystem has emerged as a significant challenge for the biotech and med-tech industries. That is a challenge that regulators are now trying to address and overcome. Read More

U.S. Senate confirms Verma as new CMS administrator

Although Seema Verma’s path through the Senate confirmation process was lined with partisan politics, a few Democrats joined their Republican colleagues to approve her as head of the Centers for Medicare & Medicaid Services (CMS) on a vote of 55-43 Monday. Read More

European Union court pushes back against EMA transparency policy

DUBLIN – The EMA’s big drive for transparency has received pushback from the Court of Justice of the European Union, which has dismissed two appeals the EMA brought against earlier court decisions that barred it from releasing trial data on two drug dossiers. Read More

Editas and Allergan ink eye disease deal, $90M up front

Allergan plc has agreed to front the genome editing company Editas Medicine Inc. $90 million plus potential milestone payments for an exclusive option to license up to five ocular programs during a seven-year term. Read More

Peloton puts pedal to the metal, extends D round to $74.6M

Peloton Therapeutics Inc. exercised an optional $22.2 million tranche of its series D round, closed in September 2016 at $52.4 million, to extend the runway for its hypoxia inducible factor-2 alpha (HIF-2 alpha) antagonists, which are targeting renal and other solid tumors. Read More

Mutational signature approach could broaden PARP inhibitors’ reach

Comprehensive analysis of mutational patterns has demonstrated that roughly 20 percent of breast tumors showed a mutational signature that was characteristic of BRCA mutations. Even without BRCA mutations, the mutational pattern suggests such tumors might have the same sensitivity to poly ADP-ribose polymerase (PARP) inhibitors as tumors with detectable BRCA mutations. Read More

EMA workshop warns of ‘orphanization’ in personalized medicine

LONDON – The EMA is standing up to defend its orphan drug legislation in the face of personalized medicines that salami slice common diseases into rare-sized subsets. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe